Weitang
Weitang is a Shanghai-based diabetes management digital health platform founded in 2012, serving diabetes patients in China. Co-founded by Feng Yanfei (CEO) and Tang New (COO), the company has raised $10.7M across two venture rounds through 2016.
- Company typePrivate
- Founded2012
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2C
- OfferingSoftware
Weitang firmographics
Firmographics- Name
- Weitang
- Legal name
- WellTang
- Website
- https://welltang.com
- Company type
- Private
- Founded year
- 2012
- Headcount range
- 101–250 employees
- Short description
- Weitang is a Shanghai-based diabetes management digital health platform founded in 2012, serving diabetes patients in China. Co-founded by Feng Yanfei (CEO) and Tang New (COO), the company has raised $10.7M across two venture rounds through 2016.
- Ownership category
- akta.pro rank
Weitang industry classification
Industry- Product category
- Diabetes Management / Digital Health
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
- akta.pro secondary industry
- Virtual Nursing, Telemonitoring & Command Center Platforms (HLACAFAH)
Keywords
Where Weitang is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Markets served
Weitang business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Domain name sales: One-time sale of domain names with optional payment plan financing (0% interest, spread across 24 monthly payments). Domain transfer to buyer occurs immediately upon purchase completion.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | One-time purchase - WellTang.com domain |
| Transaction based/ take rate | Monthly | Payment plan - WellTang.com domain |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Weitang product offering
Product offeringCore offering
Weitang operates a diabetes management platform that provides digital tools and services to help diabetes patients track, monitor, and manage their condition. The platform is targeted at individual patients in China as a digital health solution for chronic disease self-management.
Product overview
WellTang.com is a domain name asset being offered for sale through the HugeDomains marketplace. It is a single .com domain consisting of two keywords (Well + Tang), totaling 8 characters. The domain is available for immediate purchase at $2,495 or via a 24-month payment plan at $103.96/month. This is not a product or service offering from Weitang — it is a domain speculation/aftermarket listing.
Differentiator
Problem solved
Functional benefit
Products and services
- Weitang Diabetes Management Platform A consumer-facing diabetes management platform for individual diabetes patients in China, providing digital tools to track, monitor, and manage their condition as part of ongoing chronic disease self-care.
Companies that use Weitang
Customer profileSegments1 record
Ideal customer profiles1 record
Weitang technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Weitang partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NameBright.comcoreNameBright.com is the registrar partner used by HugeDomains to transfer domain names to buyers. Upon purchase, domains are pushed to buyer accounts at NameBright.com. NameBright also offers optional email packages for yearly fees and provides free WhoIs Privacy Protection for the first year.
Scale indicators1 record
Recent moves3 records
Expansion highlights2 records
Weitang competitors and assessment
Company assessmentEmerging players
- WellDoc: Diabetes digital therapeutics platform (BlueStar) offering AI-driven coaching and clinician decision support. Comparable to Weitang in applying digital tools to diabetes self-management.
Direct peers
- One Drop: B2C diabetes management platform combining a mobile app, coaching, and connected BGM hardware. Closely overlaps Weitang's chronic disease self-management positioning.
- MySugr (Roche): Consumer-facing diabetes management app (logbook, coaching, device integration) acquired by Roche. Directly comparable to Weitang as a dedicated diabetes self-management platform for patients.
- Livongo (Teladoc Health): Pioneer in chronic condition management (diabetes, hypertension, weight) using connected devices and data-driven coaching. Directly comparable business model to Weitang's diabetes platform.
- Omada Health: Virtual chronic care platform focused on diabetes prevention and management, hypertension, and behavioral health. Comparable RPM + coaching model targeting the same patient populations as Weitang.
- DarioHealth: Digital therapeutics platform for diabetes, hypertension, and musculoskeletal conditions with a connected BGM device. Operates the same chronic-condition digital health model as Weitang.
- Glooko: Diabetes data management platform that aggregates data from 95+ BGM/insulin devices for patients and clinicians. Comparable to Weitang's data integration role in diabetes management.
Regional players
- Sinocare: Leading Chinese blood glucose monitoring device manufacturer with growing digital/mobile health offerings. Closely comparable Chinese diabetes ecosystem player with adjacent device + software model.
- Yuwell: Major Chinese medical device company with blood glucose monitoring and chronic disease management products. Comparable as a Chinese chronic disease device + digital health player.
Broad incumbents
- Yidu Tech (Yidu Cloud): Strategic investor in Weitang and one of China's largest healthcare AI/data platforms serving hospitals and insurers. Highly comparable as a data-driven care infrastructure player serving overlapping stakeholders.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Weitang financial estimates
Financial estimateRevenue estimate
Valuation estimate
Weitang leadership team
Management profileNumber of profiles
Profiles2 records
Weitang funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Weitang M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Weitang
What does Weitang do?
Weitang operates a diabetes management platform that provides digital tools and services to help diabetes patients track, monitor, and manage their condition. The platform is targeted at individual patients in China as a digital health solution for chronic disease self-management.
Is Weitang a public or private company?
Weitang is a private company. It is classified as venture growth investor backed.
When was Weitang founded?
Weitang was founded in 2012. It employs 101 to 250 people.
Where is Weitang based?
Weitang is headquartered in Shanghai, China, in the Asia region.
How does Weitang make money?
One revenue line is on record: domain name sales.
Who are Weitang's main competitors?
WellDoc is listed as an emerging player. Direct peers are One Drop, MySugr (Roche), Livongo (Teladoc Health), Omada Health, DarioHealth and Glooko. Regional players are Sinocare and Yuwell. Yidu Tech (Yidu Cloud) is listed as a broad incumbent.
Does Weitang have an API?
No public API is recorded for Weitang.
What industry is Weitang in?
Weitang's product category is Diabetes Management / Digital Health. Its primary akta.pro industry code is HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity), with a secondary code of HLACAFAH, Virtual Nursing, Telemonitoring & Command Center Platforms. Its SIC code is 8000.